Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases.

Özlem AkgünFigen ÇakmakVafa GuliyevaFatma Gül Demirkan Ayşe TanatarSelda Hançerli TorunDilan ÇinSevim MeşeAli AğaçfidanNuray Aktay Ayaz

Published in: Rheumatology (Oxford, England) (2022)

Paediatric rheumatic diseases patients receiving immunomodulatory treatments were able to mount an effective humoral response after two dose regimens of BNT162b2 mRNA vaccine safely without interrupting their current treatments.

Keyphrases

immune response
emergency department
intensive care unit
young adults